Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach

J Clin Pathol. 2016 Aug;69(8):686-94. doi: 10.1136/jclinpath-2015-203456. Epub 2016 Jan 7.

Abstract

Aims: Anaplastic gliomas (AGs; WHO Grade III) include anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) and are known to have variable prognosis. Since biomarkers have a major impact on prognosis of gliomas, we compared the prognostic significance of the established biomarkers of AGs and the 'histomolecular' subgroups based on the proposed International Society of Neuropathology-Haarlem ('ISN-Haarlem') guidelines, with the current WHO 2007 classification.

Methods: The study was carried out on formalin-fixed paraffin-embedded (FFPE) tissues from 91 adult patients with AG. Clinical, histological and molecular parameters, including 1p/19q codeletion, isocitrate dehydrogenase gene (IDH1)-R132H positivity, α thalassemia/mental retardation syndrome X-linked gene (ATRX) expression and O(6)-methylguanine-DNA-methyltransferase gene (MGMT) promoter methylation (mMGMT), were correlated with overall survival (OS) and recurrence-free survival (RFS). Subsequently, following sequencing for rare IDH mutations, we derived three 'histomolecular' subgroups based on the 'integrated' diagnosis approach proposed by 'ISN-Haarlem' guidelines and correlated this with clinical outcome.

Results: Gross tumour resection, administration of radiochemotherapy, 1p/19q codeletion, IDH1-R132H positivity and mMGMT were associated with favourable OS and RFS (p≤0.001), while the WHO histological subgroups were prognostically not significant. The ISN 'histomolecular' subgroups prognosticated best with AOs (IDHmut, 1p/19q codeleted, ATRX predominantly retained) having the best survival, followed by the AAs (IDHmut, ATRX loss or retained, 1p19q non-codeleted) and AA IDH wild type group having the worst OS and RFS (p=<0.001 for OS).

Conclusions: Our study reiterates the prognostic significance of biomarkers, 1p/19q codeletion, IDH1-R132H positivity and mMGMT in AGs. Importantly, we show that the 'histomolecular' subgroups of AGs based on the 'integrated' diagnosis has a prognostic value, superior to the WHO histological classification.

Keywords: BRAIN TUMOURS; FISH; IMMUNOHISTOCHEMISTRY; MOLECULAR PATHOLOGY; NEURO-ONCOLOGY.

MeSH terms

  • Adult
  • Astrocytoma / diagnosis*
  • Astrocytoma / metabolism
  • Astrocytoma / mortality
  • Astrocytoma / pathology
  • Brain Neoplasms / diagnosis*
  • Brain Neoplasms / metabolism
  • Brain Neoplasms / mortality
  • Brain Neoplasms / pathology
  • DNA Helicases / metabolism
  • DNA Modification Methylases / metabolism
  • DNA Repair Enzymes / metabolism
  • Female
  • Humans
  • Isocitrate Dehydrogenase / metabolism
  • Male
  • Middle Aged
  • Nuclear Proteins / metabolism
  • Oligodendroglioma / diagnosis*
  • Oligodendroglioma / metabolism
  • Oligodendroglioma / mortality
  • Oligodendroglioma / pathology
  • Prognosis
  • Promoter Regions, Genetic
  • Survival Rate
  • Tumor Suppressor Proteins / metabolism
  • X-linked Nuclear Protein
  • Young Adult

Substances

  • Nuclear Proteins
  • Tumor Suppressor Proteins
  • Isocitrate Dehydrogenase
  • DNA Modification Methylases
  • MGMT protein, human
  • DNA Helicases
  • ATRX protein, human
  • X-linked Nuclear Protein
  • DNA Repair Enzymes